SCHEMBL31316615

SCHEMBL31316615

CCOC(=O)CC(C)(C#N)c1cccc(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.41
ALDH1A1 P00352 5/20 0.41
MAPK1 P28482 4/20 0.41
TDP1 Q9NUW8 2/20 0.41
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
MTNR1B P49286 1/20 0.40
MAPT P10636 5/20 0.39
RAB9A P51151 5/20 0.39
NPC1 O15118 4/20 0.39
PKM P14618 1/20 0.39
XBP1 P17861 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KDM4E B2RXH2 1/20 0.39
USP2 O75604 1/20 0.39
NFKB1 P19838 1/20 0.39
CASP1 P29466 1/20 0.39
NFKB2 Q00653 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11816273 0.86 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1MAPK1TDP1TSHR
SCHEMBL17700331 0.83 ALDH1A1 (0.45) SMN1; SMN2ALDH1A1MAPK1TDP1TSHR
SCHEMBL988620 0.83 POLB (0.47) SMN1; SMN2ALDH1A1TDP1MAPTKDM4E
SCHEMBL6898820 0.80 ALDH1A1 (0.45) SMN1; SMN2ALDH1A1MAPK1TDP1TSHR
SCHEMBL9080527 0.80 PRKCQ (0.43) ALDH1A1MAPK1CES2CES1MAPT
SCHEMBL11069800 0.78 ALDH1A1 (0.36) SMN1; SMN2ALDH1A1MAPK1TDP1TSHR
SCHEMBL11067420 0.77 BCL2 (0.35) SMN1; SMN2ALDH1A1MAPK1TDP1TSHR
SCHEMBL437664 0.76 ESR1 (0.53) ALDH1A1MAPTNPC1KDM4EMEN1
SCHEMBL3537531 0.75 CNR1 (0.44) SMN1; SMN2ALDH1A1MAPK1TDP1TSHR
SCHEMBL20349586 0.74 ALDH1A1 (0.47) SMN1; SMN2ALDH1A1MAPK1TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025010311-A1 UREA-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2 VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-01-09 WO disclosed